Zacks Investment Management Buys 928 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Zacks Investment Management raised its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 3.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 30,196 shares of the medical equipment provider's stock after buying an additional 928 shares during the period. Zacks Investment Management's holdings in Intuitive Surgical were worth $14,834,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ISRG. Hazlett Burt & Watson Inc. increased its position in Intuitive Surgical by 5.8% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 362 shares of the medical equipment provider's stock valued at $177,000 after acquiring an additional 20 shares during the period. Mitchell Mcleod Pugh & Williams Inc. grew its stake in shares of Intuitive Surgical by 4.1% in the third quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 503 shares of the medical equipment provider's stock worth $247,000 after purchasing an additional 20 shares during the last quarter. Ullmann Wealth Partners Group LLC increased its holdings in Intuitive Surgical by 1.6% in the third quarter. Ullmann Wealth Partners Group LLC now owns 1,329 shares of the medical equipment provider's stock valued at $653,000 after purchasing an additional 21 shares during the period. Meeder Advisory Services Inc. raised its position in Intuitive Surgical by 0.3% during the 3rd quarter. Meeder Advisory Services Inc. now owns 7,386 shares of the medical equipment provider's stock worth $3,629,000 after purchasing an additional 22 shares during the last quarter. Finally, One Wealth Management Investment & Advisory Services LLC lifted its holdings in Intuitive Surgical by 3.4% during the 2nd quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider's stock worth $310,000 after buying an additional 23 shares during the period. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Trading Up 0.5 %

Shares of ISRG traded up $2.76 during trading hours on Friday, reaching $550.41. The stock had a trading volume of 1,026,203 shares, compared to its average volume of 1,287,180. The firm has a 50-day simple moving average of $516.21 and a 200 day simple moving average of $474.66. Intuitive Surgical, Inc. has a 12 month low of $307.72 and a 12 month high of $556.23. The company has a market capitalization of $196.05 billion, a price-to-earnings ratio of 88.49, a P/E/G ratio of 5.41 and a beta of 1.38.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.24 by $0.32. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. The firm had revenue of $2.04 billion during the quarter, compared to analysts' expectations of $2.01 billion. On average, equities analysts forecast that Intuitive Surgical, Inc. will post 5.45 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ISRG. JPMorgan Chase & Co. raised their price objective on Intuitive Surgical from $495.00 to $575.00 and gave the stock an "overweight" rating in a research report on Friday, October 11th. Truist Financial boosted their price target on shares of Intuitive Surgical from $520.00 to $570.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. BTIG Research increased their price objective on shares of Intuitive Surgical from $535.00 to $561.00 and gave the stock a "buy" rating in a research report on Tuesday, November 26th. Piper Sandler reissued an "overweight" rating and set a $538.00 target price (up previously from $495.00) on shares of Intuitive Surgical in a research note on Friday, October 18th. Finally, Wells Fargo & Company upped their price target on shares of Intuitive Surgical from $466.00 to $549.00 and gave the company an "overweight" rating in a research report on Friday, October 18th. One research analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $541.33.

Insiders Place Their Bets

In related news, EVP Robert Desantis sold 376 shares of the business's stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $539.00, for a total transaction of $202,664.00. Following the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,967,734. The trade was a 6.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Jamie Samath sold 108 shares of the company's stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $542.06, for a total transaction of $58,542.48. Following the completion of the sale, the chief financial officer now directly owns 8,757 shares of the company's stock, valued at $4,746,819.42. The trade was a 1.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 51,023 shares of company stock valued at $26,384,247. Corporate insiders own 0.90% of the company's stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.